PremiumMarket News‘Hold the Phone,’ Says Morgan Stanley on Hims & Hers Health Stock (HIMS) ‘Too Hot to Handle,’ Analyst Warning on Hims & Hers Health Stock (HIMS) Analysts Stay Cautious on HIMS Stock amid Core Business Uncertainty PremiumRatingsCautious Outlook on Hims & Hers Health Amid Expansion and Margin Concerns Citi sees high price of Tirzepatide on Hims & Hers being ‘prohibitive’ Sell Rating for Hims & Hers Health Amid Low Margin Concerns and Competitive Pricing PremiumThe FlyHims & Hers adding access to generic liraglutide, branded tirzepatide Hims & Hers to sell Zepbound through telehealth platform, Bloomberg reports Eli Lilly threatens Zepbound copycat makers after shortage, Bloomberg reports 
